Avidity Partners Management LP 13D and 13G filings for Karyopharm Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:22 pm Sale | 2024-09-30 | 13G | Karyopharm Therapeutics Inc. KPTI | Avidity Partners Management LP | 4,741,060 3.700% | -6,447,683 (-57.63%) | Filing |
| 2024-02-14 10:33 am Sale | 2023-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI | Avidity Partners Management LP | 11,188,743 9.500% | -192,330 (-1.69%) | Filing |
| 2023-02-14 3:31 pm Purchase | 2022-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI | Avidity Partners Management LP | 11,381,073 9.900% | 29,254 (+0.26%) | Filing |
| 2022-12-08 10:22 am Purchase | 2022-12-05 | 13G | Karyopharm Therapeutics Inc. KPTI | Avidity Partners Management LP | 11,351,819 9.900% | 11,351,819 (New Position) | Filing |